Possible scenario
Regulators Slow Rollout
27% Chance
Regulators, medical boards, and hospital risk committees treat the study as promising but insufficient for broad clinical use. The most likely constraint is not technical capability, but liability, explainability, and the need for prospective trials in real care settings.
Secondary impacts
- Technology -0.5%
- Healthcare -0.1%
Tickers
- MSFT-2.1%
- GOOG-1.0%
- ORCL-0.5%
- GEHC-0.3%
Portfolio impact
S&P 500-0.3%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.